Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.

This study observed that applying a GMP-grade botanical extract to the scalp increased Bcl-2 levels, potentially preventing premature hair follicle apoptosis in chemotherapy and radiotherapy-induced alopecia.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

In this study, PRP injections into the muscular layer of rabbits' intestinal walls improved anastomosis regeneration with less adhesion compared to PRP soaking, though further research is needed to determine the best application method.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

In this first reported case, a 42-year-old female with Parry Romberg Syndrome was treated using hyaluronic acid filler, which the authors suggest may serve as a safe, simple, and cost-effective alternative to more complex surgical methods.

In this study, researchers evaluated drug-target interaction data from three major resources and developed a framework for drug repurposing, revealing associations between drug properties and therapeutic groups to aid in compound prioritization and predicting repositioning opportunities for existing drugs, particularly in cancer treatment.

In this study, a validated chromatographic method demonstrated the ability to simultaneously analyze gemcitabine and olaparib in pancreatic cancer tissues, supporting the advancement of pharmaceutical formulations combining these drugs, particularly for patients with BRCA mutations.

This study, involving a retrospective analysis of 24 patients in France, found that paradoxical psoriasiform alopecic reactions on the scalp associated with TNFα-targeted therapies for inflammatory bowel disease are rare yet non-scarring, with all patients achieving complete hair regrowth within two months after treatment adjustments.

This case report describes a 27-year-old kidney transplant recipient with end stage renal failure who developed infections and adverse reactions, ultimately resolving with antiviral treatment targeting HHV6.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.

This report describes a case of polymyositis that was resistant to steroids and immunosuppressants but showed improvement with immunoadsorption therapy.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

This study found that using valproic acid during radiotherapy for glioma was associated with delayed hair loss and improved survival outcomes.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This review discusses the traditional uses and pharmacological activities of Citrullus colocynthis, also known as Bitter Apple, but it reports no new clinical results.

This case report describes a patient with alopecia universalis who experienced quick hair regrowth after being treated with alitretinoin.

In this study, researchers found that cepharanthine significantly inhibited HSV-1 replication in vitro by interfering with specific signaling pathways, arresting the cell cycle, and inducing apoptosis in infected cells, highlighting its potential as an antiviral agent.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.

In this case report, a 45-year-old man developed acute fatal pancytopenia and other severe adverse reactions 10 days after starting albendazole and praziquantel for pulmonary cystic echinococcosis.

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This case report describes a 30-year-old Brazilian male who developed vitiligo lesions following diphencyprone therapy for alopecia areata.